Top

European Journal of Clinical Microbiology & Infectious Diseases

Published in:

01-06-2012 | Article

Invasive aspergillosis: an important risk factor on the short- and long-term survival of acute myeloid leukemia (AML) patients

Authors: M. Michallet, T. Bénet, M. Sobh, S. Kraghel, M. El Hamri, G. Cannas, F. E. Nicolini, H. Labussière, S. Ducastelle, F. Barraco, X. Thomas, Y. Chelghoum, M.-C. Nicolle, A.-L. Bienvenu, F. Persat, F. De Monbrison, S. Picot, P. Vanhems

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 6/2012

Abstract

Invasive aspergillosis (IA) during induction chemotherapy of acute myeloid leukemia (AML) could worsen the prognosis. Our objective was to study how the development of IA during AML interferes with the therapeutic strategy and to evaluate its impact on the short- and long-term survival. Newly diagnosed AML patients between the years 2004 and 2007 were retrospectively analyzed. The outcome was death of the patient. A Cox proportional hazards model with the diagnosis of IA and post-induction response evaluation as the main exposure was fitted. Overall, 262 patients were analyzed and 58 IA were observed. The 2-year survival of patients having had remission of AML was 54% and, for patients with failure of chemotherapy, it was 5% (p < 0.001). The 2-year survival of patients having had IA was 14%, and without IA, it was 32% (p = 0.01). Multivariate analysis showed that IA was associated with a higher risk of death in case of remission compared to no IA (hazard ratio [HR] = 1.66 [1.05–2.65], p = 0.031) and also in case of failure (HR = 6.43, p < 0.001). IA was associated with an increased risk of death for patients if they were either in remission or in failure after induction chemotherapy.

Michallet M, Ito JI (2009) Approaches to the management of invasive fungal infections in hematologic malignancy and hematopoietic cell transplantation. J Clin Oncol 27(20):3398–3409PubMedCrossRef

Lin SJ, Schranz J, Teutsch SM (2001) Aspergillosis case–fatality rate: systematic review of the literature. Clin Infect Dis 32(3):358–366PubMedCrossRef

Mahfouz T, Anaissie E (2003) Prevention of fungal infections in the immunocompromised host. Curr Opin Investig Drugs 4(8):974–990PubMed

Herbrecht R, Natarajan-Amé S, Letscher-Bru V, Canuet M (2004) Invasive pulmonary aspergillosis. Semin Respir Crit Care Med 25(2):191–202PubMedCrossRef

Yeghen T, Kibbler CC, Prentice HG, Berger LA, Wallesby RK, McWhinney PH, Lampe FC, Gillespie S (2000) Management of invasive pulmonary aspergillosis in hematology patients: a review of 87 consecutive cases at a single institution. Clin Infect Dis 31(4):859–868PubMedCrossRef

Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, Feld R, Pizzo PA, Rolston KV, Shenep JL, Young LS (2002) 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34(6):730–751PubMedCrossRef

Maertens J, Theunissen K, Verhoef G, Verschakelen J, Lagrou K, Verbeken E, Wilmer A, Verhaegen J, Boogaerts M, Van Eldere J (2005) Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 41(9):1242–1250PubMedCrossRef

Martino R, Viscoli C (2006) Empirical antifungal therapy in patients with neutropenia and persistent or recurrent fever of unknown origin. Br J Haematol 132(2):138–154PubMedCrossRef

Prentice HG, Kibbler CC, Prentice AG (2000) Towards a targeted, risk-based, antifungal strategy in neutropenic patients. Br J Haematol 110(2):273–284PubMedCrossRef

10.

Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, Helfgott D, Holowiecki J, Stockelberg D, Goh YT, Petrini M, Hardalo C, Suresh R, Angulo-Gonzalez D (2007) Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 356(4):348–359PubMedCrossRef

11.

Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR, Greinix H, Morais de Azevedo W, Reddy V, Boparai N, Pedicone L, Patino H, Durrant S (2007) Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 356(4):335–347PubMedCrossRef

12.

De Pauw BE, Donnelly JP (2007) Prophylaxis and aspergillosis—has the principle been proven? N Engl J Med 356(4):409–411PubMedCrossRef

13.

Pagano L, Caira M, Candoni A, Offidani M, Martino B, Specchia G, Pastore D, Stanzani M, Cattaneo C, Fanci R, Caramatti C, Rossini F, Luppi M, Potenza L, Ferrara F, Mitra ME, Fadda RM, Invernizzi R, Aloisi T, Picardi M, Bonini A, Vacca A, Chierichini A, Melillo L, de Waure C, Fianchi L, Riva M, Leone G, Aversa F, Nosari A (2010) Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study. Haematologica 95(4):644–650PubMedCrossRef

14.

Michallet M, Sobh M, Morisset S, Kraghel S, Nicolini FE, Thomas X, Bienvenu AL, Picot S, Nicolle MC, Vanhems P (2011) Risk factors for invasive aspergillosis in acute myeloid leukemia patients prophylactically treated with posaconazole. Med Mycol (in press)

15.

Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Segal BH, Steinbach WJ, Stevens DA, van Burik JA, Wingard JR, Patterson TF; Infectious Diseases Society of America (2008) Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 46(3):327–360PubMedCrossRef

16.

Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, Rees J, Hann I, Stevens R, Burnett A, Goldstone A (1998) The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children’s Leukaemia Working Parties. Blood 92(7):2322–2333PubMed

17.

Byrd JC, Mrózek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC, Pettenati MJ, Patil SR, Rao KW, Watson MS, Koduru PR, Moore JO, Stone RM, Mayer RJ, Feldman EJ, Davey FR, Schiffer CA, Larson RA, Bloomfield CD; Cancer and Leukemia Group B (CALGB 8461) (2002) Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 100(13):4325–4336PubMedCrossRef

18.

Cheson BD, Cassileth PA, Head DR, Schiffer CA, Bennett JM, Bloomfield CD, Brunning R, Gale RP, Grever MR, Keating MJ (1990) Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 8(5):813–819PubMed

19.

Herbrecht R, Letscher-Bru V, Oprea C, Lioure B, Waller J, Campos F, Villard O, Liu KL, Natarajan-Amé S, Lutz P, Dufour P, Bergerat JP, Candolfi E (2002) Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients. J Clin Oncol 20(7):1898–1906PubMedCrossRef

20.

Marr KA, Balajee SA, McLaughlin L, Tabouret M, Bentsen C, Walsh TJ (2004) Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. J Infect Dis 190(3):641–649PubMedCrossRef

21.

De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, Pappas PG, Maertens J, Lortholary O, Kauffman CA, Denning DW, Patterson TF, Maschmeyer G, Bille J, Dismukes WE, Herbrecht R, Hope WW, Kibbler CC, Kullberg BJ, Marr KA, Muñoz P, Odds FC, Perfect JR, Restrepo A, Ruhnke M, Segal BH, Sobel JD, Sorrell TC, Viscoli C, Wingard JR, Zaoutis T, Bennett JE; European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group; National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group (2008) Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 46(12):1813–1821PubMedCrossRef

22.

Maertens J, Frère P, Lass-Flörl C, Heinz W, Cornely O (2010) Antifungal prophylaxis in leukemia patients: 2009 update of the ECIL-1 and 2 guidelines. LeukemiaNet Web site. Available online at: http://www.eortc.org/home/IDG/ECIL/ECIL3_Antifungal_prophylaxis_update_2009.pdf

23.

National Comprehensive Cancer Network (NCCN) (2009) NCCN clinical practice guidelines in oncology: prevention and treatment of cancer-related infections. V.2.2009. NCCN web site. Home page at: http://www.nccn.org

24.

Pagano L, Caira M, Offidani M, Martino B, Candoni A, Valentini CG, Specchia G, Nosari A, Tosti ME, Leone G, Luppi M, Aversa F (2010) Adherence to international guidelines for the treatment of invasive aspergillosis in acute myeloid leukaemia: feasibility and utility (SEIFEM-2008B study). J Antimicrob Chemother 65(9):2013–2018PubMedCrossRef

25.

Garfield FB, Garfield JM (2000) Clinical judgment and clinical practice guidelines. Int J Technol Assess Health Care 16(4):1050–1060PubMedCrossRef

26.

Leventakos K, Lewis RE, Kontoyiannis DP (2010) Fungal infections in leukemia patients: how do we prevent and treat them? Clin Infect Dis 50(3):405–415PubMedCrossRef

27.

Sá MB, Zaragoza R (2008) Critical overview of clinical guidelines relating to invasive fungal infections. Int J Antimicrob Agents 32(Suppl 2):S155–S159PubMedCrossRef

Title: Invasive aspergillosis: an important risk factor on the short- and long-term survival of acute myeloid leukemia (AML) patients
Authors: M. Michallet
T. Bénet
M. Sobh
S. Kraghel
M. El Hamri
G. Cannas
F. E. Nicolini
H. Labussière
S. Ducastelle
F. Barraco
X. Thomas
Y. Chelghoum
M.-C. Nicolle
A.-L. Bienvenu
F. Persat
F. De Monbrison
S. Picot
P. Vanhems
Publication date: 01-06-2012
Publisher: Springer-Verlag
Published in: European Journal of Clinical Microbiology & Infectious Diseases / Issue 6/2012
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI: https://doi.org/10.1007/s10096-011-1397-5

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Invasive aspergillosis: an important risk factor on the short- and long-term survival of acute myeloid leukemia (AML) patients

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2012

Antistaphylococcal activity of Inula helenium L. root essential oil: eudesmane sesquiterpene lactones induce cell membrane damage

Clinical and phenotypic differences between classic and hypervirulent Klebsiella pneumonia: an emerging and under-recognized pathogenic variant

Characterization of IncA/C conjugative plasmid harboring bla TEM-52 and bla CTX-M-15 extended-spectrum β-lactamases in clinical isolates of Escherichia coli in Tunisia

Distribution of emm types in invasive and non-invasive group A and G streptococci

An observational efficacy and safety analysis of the treatment of acute invasive aspergillosis using voriconazole

Characterization of Th1- and Th2-type immune response in human multidrug-resistant tuberculosis

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page